Lunac Therapeutics Ltd. has synthesized coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of arthritis, Alzheimer's disease, disseminated intravascular coagulation, pulmonary embolism, myocardial infarction, diabetic retinopathy, stroke and deep venous thrombosis, among others.
LONDON – Epidarex Capital announced the closure of its £102.1 million (US$126.3 million) third fund, which will invest in very early stage biomedical and med-tech spin-outs from high-class but “under-ventured” universities in regions of the country where venture money is in short supply.